



30 September 2025

GenIP Plc

("GenIP" or the "Company")

Half year results for the period ended 30 June 2025

GenIP Plc, a technology business providing Generative Artificial Intelligence (GenAI) services to help research organisations and corporations commercialise their innovations, is pleased to announce its unaudited results for the six months ended 30 June 2025.

Melissa Cruz, CEO of GenIP, commented:

"As a new company, established in February 2024 and listed on AIM within the last 12 months, the first post-IPO year is focussed on building the strategic and operational foundations to grow and scale. With proven market demand and a service offering that was already delivering revenue at IPO we are well positioned to refine, develop, and expand that range to achieve growth, gain traction in the market and unlock shareholder value as we position for sustained growth."

GenIP's first half of 2025 has been a period of significant strategic progress, marked by international expansion, significant new client wins, and the launch of services shaped directly by market demand. We secured contracts across new markets including Saudi Arabia, Singapore, Brazil, and Chile, giving us a footprint in 25 countries globally. Our outstanding orderbook of 813k as of 30 June 2025 demonstrates both the scalability of our AI-powered model and the universality of the challenges we help clients solve. While these efforts have not yet been fully reflected in our financial results, we are confident that the second half of the year will be significantly stronger as we begin to convert our order book into recognised revenues and accelerate delivery of reports."

The momentum we are building is not just commercial but structural. Clients are turning to GenIP as an embedded partner, helping them prioritise complex portfolios, validate technologies against real market signals, and secure the talent required by new technologies to execute at pace. This reinforces our evolution from a project-based consultancy to an innovation platform, with repeatable, higher-margin workflows at its core."

Looking ahead, our priorities are clear: deepen program-level partnerships that drive recurring revenues, continue introducing client-led, high-margin services, and shift delivery toward SaaS-style engagements. At the same time, we are scaling the data assets that strengthen our competitive edge and unify our brand to create a seamless client journey."

We entered the second half of 2025 in a position of strength with 1,077k cash and cash equivalents, some of which will be used as cost of delivery for existing orders and enabling us to deliver on our strategic goals. Our growing pipeline, disciplined cost management, and expanding global footprint give us confidence in GenIP's ability to deliver sustained growth and long-term value creation for shareholders."

Business Highlights:

- Won a 350,000 contract with a Saudi Arabian research organisation to deliver 400 GenAI-enhanced Invention Evaluator analytical assessments and technology commercialisation consulting services. We expect this order to be fulfilled during this financial year.
- Secured a 65,000 contract with a Singapore-based research institute to deliver 100 GenAI-enhanced analytical assessments as part of its expansion into Asian markets through technology transfer sponsorships. We expect this order to be fulfilled during this financial year.
- Launched a new AI-powered 'Competitive Intelligence Report' that analyses market landscapes, competitive positioning, and partnership/acquisition opportunities, with a Big Four accountancy firm as its first client using the service for strategic due diligence.
- Secured our first Brazilian contract with a government research funding agency to provide AI-enhanced technology evaluation services for a national bio-energy initiative focused on commercialising sustainable energy innovations.
- Sponsored and participated in the Association of University Technology Managers (AUTM) 2025 Annual Meeting to expand our network among 3,000+ global technology transfer professionals.
- Expanded into the Republic of Chile through an engagement for 30 analytical assessment orders from a leading research institution.
- Participated in the 2025 AUTM Canadian Region Meeting to introduce our GenAI analytics services to the Canadian technology transfer community and engage with potential clients, including universities and research institutions.
- Headlined Knowledge Exchange UK 2025 with a closing keynote from our Chairman, Lord Willetts, on mission-driven knowledge exchange, providing a platform to connect with potential clients in the UK technology transfer industry.

Financial Highlights:

- 1,077k cash and equivalents as of 30 June 2025
- 813k total order book as of 30 June 2025
- 488k orders received in H1 2025
- 125k revenue in H1 2025
- 572k operating loss in H1 2025

Post Period Highlights:

- Secured our first Australian client for GenIP's Generative AI products through a government-funded consortium of universities and research organisations partnered with industry to advance technologies in advanced telecommunications, IoT connectivity, intelligent satellite systems, and next-generation Earth observation data services.
- Forged a strategic partnership with 360 Social Impact Studios, a global innovation consulting firm and venture studio, and embedded GenIP's Invention Evaluator into their venture-building methodology.
- Appointed as the official technology transfer services provider to the Chile-based GreenTech Innovation Platform as part of its strategic partnership with the Universidad Autónoma de Chile.
- Launched the Invention Validator product line - Market Validation & Buyer Perception Studies - which goes beyond market sizing to test real-world adoption. These services design and run targeted questionnaires and stakeholder interviews to measure buyer interest, evaluate pricing sensitivity, and assess packaging and positioning, turning raw research into actionable market intelligence.
- Strengthened our Talent Search business leadership with the appointment of Andrea Quiros to head Innovation & Deep Tech Talent. Andrea brings experience from IBM, Palo Alto Networks, and Amazon, and will establish scalable, data-driven recruitment solutions to help clients build the high-performing teams needed to execute commercialization strategies at pace.
- Participated in the South African Research and Innovation Management Association (SARIMA) Annual Conference and engaged with leading African institutions on technology transfer and AI adoption, strengthening GenIP's collaboration opportunities across the African continent.
- Participated in Campinas Innovation Week in Brazil, connecting with regional innovation ecosystems and expanding GenIP's presence in Latin America.
- Hosted the first webinar in a new webinar series for Technology Transfer Offices and Officers, attracting more than 20 international participants from across the innovation and commercialization sector.

Outlook

GenIP expects to drive revenue growth through new product launches, increased order closures, and accelerated deliveries. Some of the larger orders secured in the early part of the year are scheduled for fulfilment by the end of the financial year, increasing second half revenues beyond that of the first half.

GenIP is advancing its strategy to accelerate growth, improve margins, and expand its global footprint. The priorities

for the next phase of growth are:

- **Enhance revenue generation** through an expanding product offering building on the entry level product range already in the market.
- **Expand program-level partnerships** across universities, corporates, national agencies, and technology parks, with a clear objective to lift the corporate client share from ~30% to ~45% in the medium term.
- **Introduce high-margin, client-led services** that build on the Invention Evaluator foundation, progressing delivery toward SaaS-style, dashboard-led engagements.
- **Scale automation and platform efficiencies** to increase throughput from current levels while achieving and sustaining gross margins above 60%, supported by the expert human layer that ensures quality.
- **Leverage de-identified and aggregated portfolio data** to refine AI models, deliver stronger decision support, and build a compounding data advantage.
- **Extend international reach** across LATAM, Asia, and the Middle East through new partnerships and regional representatives, adding to the 25 countries where GenIP already operates.

For further information regarding GenIP, please visit www.genip.ai, or contact:

GenIP Plc
Melissa Cruz, CEO

Via Redchurch Communications

Beaumont Cornish Limited (Nominated Adviser)
Roland Cornish / Asia Szusciak / Andrew Price

Tel: +44 (0) 20 7628 3396

Novum Securities Limited (Broker)
Jon Belliss

Tel: +44 (0)20 7399 9425
JBelliss@novumsecurities.com

Redchurch Communications (Financial PR)
John Casey

genip@weareredchurch.com

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018.

Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.

Notes to Editors

About GenIP

GenIP is a next-generation consultancy at the intersection of generative AI and innovation strategy. We empower corporates, venture funds, and research institutions to evaluate, commercialise, and scale breakthrough technologies. By combining proprietary GenAI algorithms with expert human analysis, GenIP delivers decision-grade insights and talent solutions that accelerate innovation outcomes.

Service Offerings

GenIP operates through two synergistic service lines:

| Service | Description | Value Proposition |
|----------------------------|--|---|
| Invention Evaluator | AI-powered market intelligence reports assessing the commercial potential of emerging technologies | Enables faster, evidence-based decisions on R&D prioritisation, investment, and IP strategy |

| Service | Description | Value Proposition |
|---|---|--|
| Talent and Executive Search Services | Executive search platform using machine learning and NLP to match innovation-driven organisations with commercialisation-ready leadership | De-risks scaling by aligning technical vision with proven executive capability |

Together, these services form a unified GenAI-enabled platform for innovation triage and execution.

Vision & Strategy

GenIP aims to become the global leader in generative AI analytics for innovation commercialisation. Our strategy is anchored in three growth pillars:

- **Organic Expansion**
Scale Invention Evaluator and Recruitment Services through targeted outreach to corporates, VCs, and research institutions, supported by strategic marketing and digital engagement.
- **Service Deepening**
Enhance functionality and margin by expanding GenAI capabilities across both service lines-unlocking new use cases and customer segments.
- **Strategic Acquisitions**
Pursue bolt-on acquisitions of complementary GenAI services with validated market traction to broaden our offering and accelerate growth.

Forward looking statements

Certain statements contained in this announcement constitute forward-looking statements. When used in this announcement, the words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "seek", "propose", "estimate", "expect", and similar expressions, as they relate to the Company, are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial position, liquidity, prospects, growth, strategies and expectations of the industry in which the Company operates.

Such statements reflect the Company's current views with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance or achievements to materially differ from those described in this announcement. Should one or more of these risks or uncertainties materialise, or should assumptions underlying forward-looking statements prove incorrect, actual results may differ materially from those described in this announcement as "intended", "planned", "anticipated", "believed", "proposed", "estimated" or "expected".

For the avoidance of doubt, the contents of the Company's website and any hyperlinks accessible from the Company's website are not incorporated by reference into, and do not form part of, this announcement and investors should not rely on them.

CHAIRMAN'S STATEMENT

FOR THE SIX MONTH PERIOD ENDED 30 JUNE 2025

Introduction

I am pleased to present GenIP Plc's Interim Financial Statements for the period to 30 June 2025. These results reflect the first six months of trading without significant corporate events and enabling the team to focus on developing the business.

The significant events of 2024 which included establishing the company, acquiring the core business assets and securing initial funding through listing on AIM were the first steps towards positioning ourselves as a leader in technology transfer, leveraging AI-driven solutions to support universities, research organisations, and technology companies.

Performance

During the six months to 30 June 2025, GenIP generated 125,166 in revenue while incurring a loss before taxation of 565,585, reflecting the full staff and operational costs, including marketing and advertising required of start-up company in the early stages of investment to building and scale our operations. The operating loss of 571,630 primarily stemmed from marketing and advertising, director and staff costs and share based payments. The substantial share-based payments incurred in 2024 were replaced by significant uplifts in marketing efforts and expanding and developing the team to target scalable and profitable growth.

The cash balance at 30 June 2025 of 1,076,818 reflects the successful growth in the order book and the benefits achieved by several clients paying in advance. Income is reflected upon delivery of the services.

Since the 30 June and outlook

The opportunities unfolding in 2025, which include successes in winning new customers in new territories and markets is encouraging. The strategic integration of AI across our Invention Evaluator platform and executive recruitment workflows is not only elevating the precision and impact of our services-it's redefining how innovation is assessed, matched, and mobilised across sectors.

GenIP is well positioned to meet the market demand for university-led commercialisation and in other technology driven markets and high-calibre executive recruitment within innovation-driven enterprises. Our focus remains on deepening client partnerships, sharpening our service portfolio, and unlocking operational efficiencies that scale with purpose.

The Board remains firmly committed to disciplined financial stewardship while actively supporting strategic investments that accelerate growth, strengthen our market position, and deliver long-term value to shareholders.

Lord D L Willetts

Independent Non-Executive Chairman

Date: 30th September 2025

CHIEF EXECUTIVE'S SUMMARY

FOR THE SIX MONTH PERIOD ENDED 30 JUNE 2025

Introduction and Strategy

GenIP is entering its next phase of growth as an AI-powered platform-led consultancy. In just a short time we have expanded into 25 countries and secured contracts that demonstrate strong and growing global demand. From Saudi Arabia and Singapore to Brazil and Chile, clients are choosing GenIP because we help them move beyond one-off evaluations to a complete decision making and execution framework.

With the Invention Evaluator report as the trusted entry point, every new service builds directly on that foundation,

enabling clients to evaluate and rank portfolios, test real buyer interest, and advance the strongest opportunities through licensing, spin-outs, partnerships and talent placement.

This shift is transforming our business model from projects to platform, from transactions to recurring revenues. It allows us to deliver consistency and efficiency through automation, while layering in the strategic oversight that makes us a long-term partner of choice for research organisations, corporates and investors navigating the future of innovation.

GenIP is consolidating its brand architecture by bringing Invention Evaluator and Talent Search (Vortechs) under a unified GenIP.ai platform identity. This strategic consolidation creates clear service tiers and integrated cross-selling opportunities whilst simplifying the client experience across all touchpoints. The Invention Evaluator will remain the flagship product, leveraging its existing market recognition, while Vortechs will be rebranded as GenIP Talent and Executive Search services to leverage the Company's brand recognition. This evolution towards a platform-led consultancy model establishes the foundation for recurring SaaS-style revenues, margin expansion through automation, and defensible IP assets that strengthen GenIP's long-term strategic position.

The company is launching a comprehensive suite of new products and services designed to transform GenIP into a complete innovation platform. All new offerings are powered by the highly automated Invention Evaluator platform and workflow, with consulting services streamlined through internal dashboards that enable human consultants to focus on oversight and service delivery. These new product lines are specifically designed to deepen relationships with existing clients and create high-margin consulting pathways as add-on services to the entry-level Invention Evaluator report.

Performance

The last quarter of 2024, following the IPO, and the first half of 2025 has been a period of laying the foundation for growth by attending key industry events, getting GenIP and its products in front of as many customers as possible and securing new business and orders. This resulted in significant orders from Asia and Latin America for future delivery as reflected in the growth of our deferred income balance.

Sales in the period were modestly ahead of the last half of 2024, following the acquisition of the business and assets in June 2024 with margins increasing slightly.

Operating costs increased as the advertising and marketing campaigns were activated and the business started to reflect the full costs of staff and professional fees, replacing the substantial share-based payments from last year.

Since June, we have started to deliver some of the larger orders and expect second half revenues to be significantly better than the first half, whilst also using some of the cash reserves as cost of delivery. Delivery of these orders should lead to repeat orders at a later date.

We continue to build the orderbook, develop the product line and add new and key staff:

- Signed and agreed strategic partnerships and government backed programmes across Australia, Chile, Africa and Latin America with University consortiums and securing new corporate clients.
- Appointed a Head of Innovation and Deep Tech Talent to lead the recruitment services side of the business.
- Launched the Invention Validator product line which measures buyer interest, evaluates price sensitivity, turning research data into actionable market intelligence.

Outlook

GenIP is entering a pivotal phase with a clear plan to accelerate growth and strengthen its market position. Our focus is on growing an AI powered platform led model while deepening client relationships and expanding globally.

Ms M Cruz

Chief Executive Officer

Date: 30th September 2025

Introduction

GenIP Plc presents its unaudited interim financial results for the 6 months ending 30 June 2025.

The Company was incorporated on 23 February 2024, acquired the business and assets of Invention Evaluator and Vortechs on 4 June 2024 and was admitted to AIM and completed a fundraising by way of a placing and subscription for shares on 2 October 2024 raising gross proceeds of approximately £1.75m.

Comparative amounts are presented for the periods ending 30 June 2024 and 31 December 2024. Trading in these periods was significantly different as the company was established, obtained funding and staffed up to begin operating the business.

The financial statements are presented in US Dollars which is the Company's presentational and functional currency.

Financial Highlights - period ended 30 June 2025

| | Six months ended 30 June 2025 | Six months ended 30 June 2024 | Period ended 31 December 2024 |
|---------------------|----------------------------------|----------------------------------|----------------------------------|
| | US | US | US |
| Revenue | 125,166 | 18,207 | 123,015 |
| Gross Profit Margin | 22,620 | 4,838 | 15,158 |
| Operating Loss | (571,630) | (67,372) | (888,545) |
| Net Assets | 745,382 | 187,994 | 1,272,122 |
| Cash balances | 1,076,818 | - | 972,364 |

Revenue

Revenue in the 6-month period was 125k (June 2024: 18k), generating a margin of 23k (18.1%), slightly more than the 7 months to December 2024 (123k), following the transfer of the business. Invention Evaluator turnover was 112k (Dec 2024: 99k) and Vortechs turnover was 13k (Dec 2024: 24k) in the 6 months to June 2025.

Administrative Expenses

Administrative expenses were 694k representing the full costs of the business for 6-months to June 2025, made up of directors and staff costs 229k, marketing and advertising costs 155k, legal and professional costs 186k and share based payments of 62k. The comparative period to June 2024 includes establishment costs of the business - staff costs 7k, management charges from Tekcapital Plc 39k and other establishment costs. The comparative period to December 2024 includes 3 months of business costs following the IPO in October 2024, made up of director and staff costs 120k, marketing and advertising costs 52k, legal and professional costs 219k and 359k of share-based payments.

Operating Loss

Operating loss was 571k, after the administrative expenses and cost of sales and reflects the early-stage investment to scale the business and strengthen our offerings and market position.

Intangible Assets

Intangible assets are made up of the technology assets transferred upon acquisition in June 2024 and development costs of 120k incurred on Invention Evaluator after the transfer. Further product enhancement and development work is being undertaken on Invention Evaluator due to come into effect in Q4 2025. 10k was incurred in the period to develop the website.

In March 2025, Tekcapital PLC agreed to reimburse the Company 100k of the 120k IT development costs incurred in 2024. The Company continues to benefit from the expenditure which remains capitalised as an Intangible Asset. This reimbursement is being recognised as Other Operating Income, payable over 2 years.

Cash Flows

Cash and cash equivalents at the balance sheet date was 1,077k (June 2024: nil; December 2024: 972k).

Cash generated by operations was 242k reflecting the pay-in-advance terms obtained from several Invention Evaluator customers.

Cash absorbed by operations was 55k in the period to June 2024 and 557k in the period to December 2024.

Debt financing and liquidity

In March 2025 Tekcapital Group agreed to offset the balances owed and owing on the Convertible Loan Note and the Inter-company Receivable and transfer any residual amount to the Inter-company balance and close the Convertible Loan Note, with an effective date of 31 December 2024. IFRS required this to be disclosed as a non-adjusting post balance sheet event in financial statements to 31 December 2024. The balances on the Convertible Loan Note and the Inter-company receivable at 31 December 2024 were 134k and were 120k respectively. The receivable balance on the Inter-company account at 30 June 2025 was 115k, made up of the contribution to IT development costs of 88k and recovery of other funds due of 27k.

The company has no other debt.

Share based payments

Share based payments to incentivise and retain key personnel, together with options and warrants granted have been valued using the Black-Scholes model with the fair value of these payments, warrants and options being expensed over the vesting period.

Total share-based payment expense 62k recognized in the period ended 30 June 2025 (nil in the period to 30 June 2024; 359k in the period to 31 December 2024).

This ensures cost efficiency while rewarding performance, enhancing alignment between management and shareholders.

Going Concern

The Directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. For this reason, they continue to adopt the Going Concern basis in preparing the financial statements.

Performance against KPI's

GenIP Plc tracks several financial and operational metrics, including:

- Revenue Growth: Expanding client acquisition
- Gross Margin: Improving cost efficiency
- Cash Flow Management: Maintaining liquidity
- Client Engagement: Strengthening relationships across sectors

The Key Performance Indicators (KPI's) listed below represent those that are typically applied to technology service companies and serve as a starting point for evaluating the Company's performance and guide decision making, to ensure long-term sustainability.

| KPI | Description | Jun-25 | Jun-24 | Dec-24 |
|--------------|---|---------|--------|---------|
| Total Income | Total Income including revenue from Invention | 425,466 | 49,007 | 422,045 |

| | | | | |
|---------------------|---|---------|-----------|------------|
| Total income | Total income including revenue from invention Evaluator and Vortechs Sales | 125,166 | 18,207 | 123,015 |
| Gross Profit Margin | Percentage of revenue remaining after deducting cost of sales | 18.1% | 26.6% | 12.3% |
| Operating Cash Flow | Net cash generated (absorbed) from business operations before financing activities. | 241,951 | (54,917) | (556,642) |

STATEMENT OF COMPREHENSIVE INCOME (UNAUDITED)
FOR THE SIX MONTH PERIOD ENDED 30 JUNE 2025

| | Six months ended 30 June 2025 Unaudited | Period ended 30 June 2024 Unaudited | Period ended 31 December 2024 Audited |
|---|--|--|--|
| Revenue | 125,166 | 18,207 | 123,015 |
| Cost of sales | (102,546) | (13,369) | (107,857) |
| Gross profit | 22,620 | 4,838 | 15,158 |
| Other operating income | 100,000 | - | - |
| Administrative expenses | (694,250) | (72,210) | (903,703) |
| Operating loss | (571,630) | (67,372) | (888,545) |
| Investment revenues | 6,045 | - | 1,813 |
| Finance costs | - | (2) | (97) |
| Loss before taxation | (565,585) | (67,374) | (886,829) |
| Income tax expense | - | - | - |
| Loss and total comprehensive income for the Six month period | (565,585) | (67,374) | (886,829) |
| | Six months ended 30 June 2025 Unaudited | Period ended 30 June 2024 Unaudited | Period ended 31 December 2024 Audited |
| Earnings per share | | | |
| Basic | (0.035) | (0.000) | (0.051) |
| Diluted | (0.026) | (0.000) | (0.037) |

In the six months ended 30 June 2025 other comprehensive income was nil (period ended 30 June 2024: nil; period ended 31 December 2024: nil).

All items dealt within arriving at the loss for the six months ended 30 June 2025 are attributable to the equity holders of the Company and relate to continuing operations.

The notes below form part of these financial statements.

STATEMENT OF CHANGES IN EQUITY (UNAUDITED)

FOR THE SIX MONTH PERIOD ENDED 30 JUNE 2025

| | Share capital | Share premium account | Capital redemption reserve | Options & warrant reserve | Retained earnings | Total |
|--|---------------|-----------------------|----------------------------|---------------------------|-------------------|-----------|
| Notes | | | | | | |
| Balance at 1 January 2025 | 102,097 | 1,530,040 | 191,564 | 335,250 | (886,829) | 1,272,122 |
| Period ended 30 June 2025: | | | | | | |
| Loss and total comprehensive income | - | - | - | - | (565,585) | (565,585) |
| Transactions with owners: | | | | | | |
| Share based payment | - | - | - | 38,845 | - | 38,845 |
| Balance at 30 June 2025 (Unaudited) | 102,097 | 1,530,040 | 191,564 | 374,095 | (1,452,414) | 745,382 |
| Balance at 23 February 2024 | - | - | - | - | - | - |
| Period ended 30 June 2024: | | | | | | |
| Loss and total comprehensive income | - | - | - | - | (67,374) | (67,374) |
| Transactions with owners: | | | | | | |
| Issue of share capital | 63,804 | - | - | - | - | 63,804 |
| Capital contribution | - | - | 191,564 | - | - | 191,564 |
| Balance at 30 June 2024 (Unaudited) | 63,804 | - | 191,564 | - | (67,374) | 187,994 |
| Balance at 23 February 2024 | - | - | - | - | - | - |
| Period ended 31 December 2024: | | | | | | |
| Loss and total comprehensive income | - | - | - | - | (886,829) | (886,829) |
| Transactions with owners: | | | | | | |
| Issue of share capital | 102,097 | 2,426,362 | - | - | - | 2,528,459 |
| Cost of share issue | - | (896,322) | - | - | - | (896,322) |
| Share based payment | - | - | - | 335,250 | - | 335,250 |
| Capital contribution | - | - | 191,564 | - | - | 191,564 |
| Balance at 31 December 2024 (Audited) | 102,097 | 1,530,040 | 191,564 | 335,250 | (886,829) | 1,272,122 |

The notes on pages 9 to 16 form part of these financial statements.

STATEMENT OF CASH FLOWS (UNAUDITED)

FOR THE SIX MONTH PERIOD ENDED 30 JUNE 2025

| | | Six months ended 30 June 2025 Unaudited | Period ended 30 June 2024 Unaudited | Period ended 31 December 2024 Audited |
|--|---|---|-------------------------------------|---------------------------------------|
| Notes | | | | |
| Cash flows from operating activities | | | | |
| Cash generated from/(absorbed by) operations | 8 | 241,951 | (54,917) | (556,642) |

| | | | |
|---|------------------|-----------------|------------------|
| Interest paid | - | (2) | (97) |
| Net cash inflow/(outflow) from operating activities | 241,951 | (54,919) | (556,739) |
| Investing activities | | | |
| Purchase of intangible assets | (9,972) | (44,547) | (126,306) |
| Interest received | 6,045 | - | 1,813 |
| Net cash used in investing activities | (3,927) | (44,547) | (124,493) |
| Financing activities | | | |
| Proceeds from issue of shares | - | 63,804 | 2,358,668 |
| Share issue costs | - | - | (838,642) |
| Issue of convertible loans | - | 35,662 | 133,570 |
| Repayment of convertible loans | (133,570) | - | - |
| Net cash (used in)/generated from financing activities | (133,570) | 99,466 | 1,653,596 |
| Net increase in cash and cash equivalents | 104,454 | - | 972,364 |
| Cash and cash equivalents at beginning of year | 972,364 | - | - |
| Cash and cash equivalents at end of year | 1,076,818 | - | 972,364 |

The notes on pages 9 to 16 form part of these financial statements.

NOTES TO THE FINANCIAL STATEMENTS

FOR THE SIX MONTH PERIOD ENDED 30 JUNE 2025

1 Basis of preparation

Company

information

GenIP PLC is a public company limited by shares incorporated in England and Wales. The registered office is 12 New Fetter Lane, London, EC4A 1JP.

Nature of operations

The principal activity of the company continued to be that of empowering organisations to better evaluated and commercialise their discoveries through two distinct, yet complementary, services:

- Invention Evaluator - providing bespoke enhanced research reports assessing the market potential for new technologies innovations and discoveries by utilising artificial intelligence driven proprietary software; and
- Vortechs - providing executive recruitment services to match technology organisations with experienced executives and business leaders also using artificial intelligence driven software and proprietary data.

Reporting period

The company was incorporated on 23 February 2024. As such, the comparative figures stated in these interim financial statements relate to the period from 23 February 2024 - 30 June 2024 and the 23 February 2024 - 31 December 2024. The current period relates to 1 January 2025 - 30 June 2025.

General information and statement of compliance with IFRS Accounting Standards

The interim financial statements are for the six months ended 30 June 2025 and are presented in US dollars,

which is the functional currency of the company. All monetary amounts are rounded to the nearest US dollar unless otherwise stated.

The interim financial statements have been prepared in accordance with IAS 34 'Interim Financial Reporting' as issued by the International Accounting Standards Board. They do not include all of the information required in annual financial statement in accordance with IFRS Accounting Standards and should be read in conjunction with the financial statements for the period ended 31 December 2024.

The company's shares were admitted to trading on AIM, a market operated by the London Stock Exchange, on 2 October 2024.

Accounting policies

The Interim Financial Statements have been prepared in accordance with the accounting policies adopted in the company's most recent annual financial statements for the period ended 31 December 2024.

2 Segmental analysis

The company has two operating segments: Invention Evaluator and Vortechs. During the six month period to 30 June 2025, there have been no changes from prior periods in the management methods used to determine operating segments and reported segment profit and loss.

The revenues and profits generated by each of the company's segments and segment assets and liabilities are summarised as follows:

2 Segmental analysis

Period ended 30 June 2025

| | Invention Evaluator | Vortechs | Unallocated | Total |
|--|------------------------|----------|-------------|-----------|
| | US | US | US | US |
| Segmental income statement | | | | |
| Revenue | 111,666 | 13,500 | | 125,166 |
| Cost of Sales | (91,885) | (10,661) | | (102,546) |
| Operating costs | (241,203) | (29,706) | (275,465) | (546,374) |
| Depreciation and amortisation | (22,876) | (25,000) | | (47,876) |
| Operating loss | (244,298) | (51,867) | (275,465) | (571,630) |
| Interest income / (expense) | 0 | 0 | 6,045 | 6,045 |
| Loss on ordinary activities before tax | (244,298) | (51,867) | (269,420) | (565,584) |
| Tax | 0 | 0 | 0 | 0 |
| Loss on ordinary activities after tax | (244,298) | (51,867) | (269,420) | (565,584) |
| Segmental statement of financial position | | | | |
| Assets | 177,999 | 52,358 | 1,249,310 | 1,479,667 |
| Liabilities | (530,387) | (2,666) | (201,231) | (734,284) |
| Net assets / (liabilities) | (352,388) | 49,692 | 1,048,079 | 745,383 |
| Other segmental items | | | | |
| Capital expenditure | 0 | 0 | 9,972 | 9,972 |

Period ended 30 June 2024

| | Invention Evaluator | Vortechs | Unallocated | Total |
|--|------------------------|----------|-------------|----------|
| | US | US | US | US |
| Segmental income statement | | | | |
| Revenue | 13,874 | 4,333 | - | 18,207 |
| Cost of Sales | (12,225) | (1,144) | - | (13,369) |
| Operating costs | (17,678) | (5,633) | (48,899) | (72,210) |
| Depreciation and amortisation | - | - | - | - |
| Operating loss | (16,029) | (2,444) | (48,899) | (67,372) |
| Interest income / (expense) | - | - | - | - |
| Loss on ordinary activities before tax | (16,029) | (2,444) | (48,899) | (67,372) |
| Tax | - | - | - | - |
| Loss on ordinary activities after tax | (16,029) | (2,444) | (48,899) | (67,372) |
| Segmental statement of financial position | | | | |
| Assets | 168,028 | 104,353 | 108,643 | 381,024 |

| | | | | |
|------------------------------|-----------|---------|----------|-----------|
| Liabilities | (124,106) | - | (68,923) | (193,029) |
| Net assets / (liabilities) | 43,922 | 104,353 | 39,720 | 187,995 |
| Other segmental items | | | | |
| Capital expenditure | 44,547 | - | - | 44,547 |

2 Segmental analysis

(Continued)

Period ended 31 December 2024

| | Invention Evaluator | Vortechs | Unallocated | Total |
|--|------------------------|----------|-------------|-----------|
| | US | US | US | US |
| Segmental income statement | | | | |
| Revenue | 99,349 | 23,666 | - | 123,015 |
| Cost of Sales | (98,655) | (9,202) | - | (107,857) |
| Operating costs | (117,463) | (11,066) | (720,987) | (849,516) |
| Depreciation and amortisation | (27,192) | (26,995) | - | (54,187) |
| Operating loss | (143,961) | (23,597) | (720,987) | (888,545) |
| Interest income / (expense) | - | - | 1,716 | 1,716 |
| Loss on ordinary activities before tax | (143,961) | (23,597) | (719,271) | (886,829) |
| Tax | - | - | - | - |
| Loss on ordinary activities after tax | (143,961) | (23,597) | (719,271) | (886,829) |
| Segmental statement of financial position | | | | |
| Assets | 175,027 | 77,357 | 1,214,108 | 1,376,492 |
| Liabilities | (111,450) | (308) | (247,978) | (359,736) |
| Net assets / (liabilities) | 63,577 | 77,049 | 876,130 | 1,016,756 |
| Other segmental items | | | | |
| Capital expenditure | 119,655 | - | 6,651 | 126,306 |

3 Intangible assets

| | Invention Evaluator | Vortechs | Website | Total |
|------------------------------------|------------------------|----------|---------|---------|
| Cost | | | | |
| At 1 January 2025 | 517,428 | 462,771 | 6,651 | 986,850 |
| Additions | - | - | 9,972 | 9,972 |
| At 30 June 2025 | 517,428 | 462,771 | 16,623 | 996,822 |
| Amortisation and impairment | | | | |
| At 1 January 2025 | 346,071 | 385,413 | - | 731,484 |
| Charge for the period | 22,875 | 25,000 | - | 47,875 |
| At 30 June 2025 | 368,946 | 410,413 | - | 779,359 |
| Carrying amount | | | | |
| At 30 June 2025 | 148,482 | 52,358 | 16,623 | 217,463 |
| At 31 December 2024 | 171,357 | 77,358 | 6,651 | 255,366 |
| | Invention Evaluator | Vortechs | Website | Total |
| Cost | | | | |
| At 23 February 2024 | - | - | - | - |

| | | | | |
|------------------------------------|----------------|----------------|---------------|----------------|
| At 23 February 2024 | - | - | 44,547 | 44,547 |
| Additions | - | - | - | - |
| Transfer of assets | 397,773 | 462,771 | - | 860,544 |
| | <u>397,773</u> | <u>462,771</u> | <u>44,547</u> | <u>905,091</u> |
| At 30 June 2024 | 397,773 | 462,771 | 44,547 | 905,091 |
| Amortisation and impairment | | | | |
| At 23 February 2024 | - | - | - | - |
| Transfer of assets | 318,879 | 358,418 | - | 677,297 |
| | <u>318,879</u> | <u>358,418</u> | <u>-</u> | <u>677,297</u> |
| At 30 June 2024 | 318,879 | 358,418 | - | 677,297 |
| Carrying amount | | | | |
| At 30 June 2024 | <u>78,894</u> | <u>104,353</u> | <u>44,547</u> | <u>227,794</u> |
| At 23 February 2024 | <u>-</u> | <u>-</u> | <u>-</u> | <u>-</u> |

3 Intangible assets

(Continued)

| | Invention Evaluator | Vortechs | Website | Total |
|------------------------------------|------------------------|----------------|--------------|----------------|
| Cost | | | | |
| At 23 February 2024 | - | - | - | - |
| Additions | 119,655 | - | 6,651 | 126,306 |
| Transfer of assets | 397,773 | 462,771 | - | 860,544 |
| | <u>517,428</u> | <u>462,771</u> | <u>6,651</u> | <u>986,850</u> |
| At 30 June 2025 | 517,428 | 462,771 | 6,651 | 986,850 |
| Amortisation and impairment | | | | |
| At 23 February 2024 | - | - | - | - |
| Charge for the year | 27,192 | 26,995 | - | 54,187 |
| Transfer of assets | 318,879 | 358,418 | - | 677,297 |
| | <u>346,071</u> | <u>385,413</u> | <u>-</u> | <u>731,484</u> |
| At 31 December 2024 | 346,071 | 385,413 | - | 731,484 |
| Carrying amount | | | | |
| At 31 December 2024 | <u>171,357</u> | <u>77,358</u> | <u>6,651</u> | <u>255,366</u> |
| At 23 February 2024 | <u>-</u> | <u>-</u> | <u>-</u> | <u>-</u> |

4 Trade and other receivables

| | 30 June 2025 | 30 June 2024 | 31 December 2024 |
|--|-----------------|-----------------|---------------------|
| Trade receivables | 18,638 | 62,898 | 23,558 |
| Provision for bad and doubtful debts | (17,179) | (18,311) | (19,888) |
| | <u>1,459</u> | <u>44,587</u> | <u>3,670</u> |
| VAT recoverable | 27,461 | 23,775 | 196,588 |
| Amounts owed by related parties (Note 7) | 114,555 | 29,840 | 120,383 |
| Prepayments | 96,421 | - | 83,487 |
| Prepaid IPO costs | - | 55,028 | - |
| | <u>239,896</u> | <u>153,230</u> | <u>404,128</u> |

| 5 | Trade and other payables | 30 June 2025 | 30 June 2024 | 31 December 2024 |
|---|------------------------------------|-----------------|-----------------|------------------------|
| | Trade payables | 191,235 | 56,638 | 25,406 |
| | Accruals | 173,024 | 12,167 | 117,983 |
| | Social security and other taxation | 4,675 | - | 4,383 |
| | Other payables | 1,526 | - | - |
| | | <u>370,460</u> | <u>68,805</u> | <u>147,772</u> |

| 6 | Share-based payments | | Number of share Average options and exercise price warrants Number |
|---|---------------------------------|-------------|--|
| | Outstanding at 23 February 2024 | - | - |
| | Granted in the period | - | - |
| | | <hr/> | <hr/> |
| | Outstanding at 30 June 2024 | - | - |
| | Exercisable at 30 June 2024 | - | - |
| | | <hr/> <hr/> | <hr/> <hr/> |
| | Outstanding at 1 July 2024 | - | - |
| | Granted in the period | 5,628,418 | 0.58 |
| | | <hr/> | <hr/> |
| | Outstanding at 31 December 2024 | 5,628,418 | 0.58 |
| | Exercisable at 31 December 2024 | 4,865,383 | 0.58 |
| | | <hr/> <hr/> | <hr/> <hr/> |
| | Outstanding at 1 January 2025 | 5,628,418 | 0.58 |
| | Granted in the period | - | - |
| | | <hr/> | <hr/> |
| | Outstanding at 30 June 2025 | 5,628,418 | 0.58 |
| | Exercisable at 30 June 2025 | 4,865,383 | 0.58 |

Share options and warrants outstanding at the end of the period have the following expiry dates and exercise prices:

(Continued)

| | | | 30 June 2025 | 30 June 2024 | 31 December 2024 |
|-------------------|----------------|----------------|------------------|--------------|---------------------|
| Grant date | Expiry date | Exercise price | Number | Number | Number |
| 17 July 2024 | 17 July 2027 | £0.39 (0.53) | 215,917 | - | 215,917 |
| 5 August 2024 | 5 August 2027 | £0.39 (0.53) | 332,200 | - | 332,200 |
| 9 August 2024 | 9 August 2027 | £0.39 (0.53) | 215,917 | - | 215,917 |
| 26 September 2024 | 2 October 2029 | £0.39 (0.53) | 217,949 | - | 217,949 |
| 26 September 2024 | 2 October 2027 | £0.39 (0.53) | 160,256 | - | 160,256 |
| 26 September 2024 | 2 October 2027 | £0.43 (0.59) | 4,487,179 | | 4,487,179 |
| | | | <u>5,629,418</u> | <u>-</u> | <u>5,629,418</u> |
| | | | 30 June 2025 | 30 June 2024 | 31 December 2024 |

| | | | |
|--|--------|---|---------|
| Expenses | | | |
| Related to equity settled share based payments | 62,068 | - | 358,924 |

7 Related party transactions

Phosphorix Ltd

The Company entered into a master services agreement with Phosphorix Ltd, a company owned and operated by the CTO of GenIP Plc. Phosphorix Ltd operates the Invention Evaluator platform and provides IT development services to the Company. Pricing and costing is on an arm's length basis. In the period to 30 June 2025, the company incurred 88,943 of cost of sales of which 30,928 was outstanding at the reporting date.

Guident Limited

During the period to 30 June 2025, 8,000 of Vortechs sales were made to Guident Limited, a related party by virtue of common control.

Tekcapital PLC

After the 31 December 2024 balance sheet date, Tekcapital PLC, the Company's majority shareholder, agreed to contribute 100,000 of the 119,665 IT development costs incurred by the Company in 2024. This contribution to be paid over 24 months. GenIP continues to benefit from the expenditure, which has been capitalised as an Intangible Asset. This agreement was a non-adjusting post balance sheet event in the 31 December 2024 accounts. The balance outstanding at 30 June 2025 was 87,506. A further 27,049 was due relating to other payments received by Tekcapital on behalf of GenIP.

7 Related party transactions

(Continued)

Convertible Loan Note

After the 31 December 2024 balance sheet date, Tekcapital Group agreed to offset the balances owed and owing on the Convertible Loan Note and the Inter-company Receivable and transfer any residual amount to the Inter-company balance and close the Convertible Loan Note with an effective date of 31 December 2024. This was disclosed in the 2024 accounts as a non-adjusting event in the 2024 accounts.

| | 31 Dec 2024 | Offset | Adjustment | 31 Dec 2024 |
|-------------------|-------------|-----------|------------|-------------|
| | US | US | US | US |
| Tekcapital Europe | 133,570 | (120,383) | (13,187) | - |
| Tekcapital LLC | (120,383) | 120,383 | 13,187 | 13,187 |

8 Cash absorbed by operations

| | Six months ended 30 June 2025 | Period ended 30 June 2024 | Period ended 31 December 2024 |
|--|--|------------------------------------|--|
| Loss for the Six month period before taxation | (565,585) | (67,374) | (886,829) |
| Adjustments for: | | | |
| Finance costs | - | 2 | 97 |
| Investment income | (6,045) | - | (1,813) |
| Amortisation and impairment of intangible assets | 47,876 | - | 54,187 |
| Equity settled share based payment expense | 62,068 | - | 358,924 |
| Movements in working capital: | | | |
| Increase in trade and other receivables | 164,232 | (41,263) | (257,329) |
| Increase in trade and other payables | 199,464 | 45,030 | 147,772 |
| Increase in deferred revenue outstanding | 339,941 | 8,688 | 28,349 |

Cash absorbed by operations

241,951

(54,917)

(556,642)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

IR DKLFLEKLFBBZ